0
฿0.00
An empty cart
You have no item in your shopping cart
Product Category · Pharmaceutical IndustryPharmaceutical Process FiltrationSterile 0.2 Micron
Pharmaceutical Process FiltrationSterile 0.2 Micron
& Final Drug Filtration
Validated pharmaceutical process filtration systems play a critical role in sterile pharmaceutical manufacturing. Every parenteral drug product, sterile API solution, and purified water stream must pass through carefully controlled filtration stages before reaching the final filling process. Sterilizing-grade membrane filters, typically rated at 0.2 µm, are used as the final barrier for microbial removal before filling operations. Pharmaceutical filtration systems must support regulatory requirements for validation, bacterial challenge testing, and pre- and post-use integrity testing in accordance with EU GMP Annex 1, FDA, and WHO guidelines.
✓ 0.2 µm Sterilizing Grade ✓ Integrity Test Certified ✓ Bacterial Challenge Validated ✓ E&L Tested
System Overview
Key Specifications
Sterilizing Grade0.2 µm membrane — LRV ≥10⁷ validated
MembranePES, PVDF, PTFE, Nylon — product specific
Integrity TestBubble point / Forward flow — pre & post use
E&L TestingExtractables & leachables per ICH Q3D/USP
ValidationBacterial challenge test — Brevundimonas dim.
ComplianceEU GMP Annex 1, FDA 21 CFR, USP <1229.3>
✓ 0.2 µm Sterilizing Grade ✓ LRV ≥10⁷ Validated ✓ Pre & Post Integrity Test ✓ Extractables Tested ✓ IQ/OQ Documentation
Industry Overview
Why Sterile Filtration Is the Most Regulated Step in Pharmaceutical Manufacturing
Pharmaceutical process filtration encompasses all filtration steps from bulk drug substance handling through to sterile drug product manufacturing — but none carries more regulatory weight than sterile filtration in pharmaceutical manufacturing at the final 0.2 µm step before aseptic filling. EU GMP Annex 1 (2022 revision), FDA's Guidance on Sterile Drug Products Produced by Aseptic Processing, and WHO Technical Report Series all require that sterilizing-grade filters be validated, integrity-tested before use, integrity-tested after use, and that a failed post-use integrity test trigger an investigation of the batch produced through the failed filter — regardless of other sterility test results.
The liquid filtration for pharmaceutical production train upstream of the sterilizing filter is equally critical: inadequately pre-filtered bulk drug solutions can cause premature loading and early failure of the sterilizing filter, increasing the risk of a post-use integrity test failure. A properly designed pharmaceutical solution filtration system uses a staged approach — clarifying pre-filtration removes bulk particles and extractables, depth filtration removes sub-micron particles and colloids that would blind the sterilizing membrane, and the 0.2 µm sterilizing filter performs the microbial removal filtration pharma step with its full validated capacity available.
Every membrane filters for pharmaceutical applications selection and every filter housing specification must also consider extractables and leachables — the chemical compounds that migrate from the filter material into the filtered drug product. For parenteral products, regulatory agencies require documented extractables testing under worst-case conditions and a patient safety assessment against ICH Q3D elemental impurities limits and product-specific toxicological thresholds.
- 0.2 µm sterilizing membrane — LRV ≥10⁷ per bacterial challenge test validation
- Pre & post-use integrity testing — bubble point or forward flow on every batch
- Staged filter train — clarification, depth filtration, sterilizing 0.2 µm
- Membrane chemistry matched to drug product — PES, PVDF, PTFE, Nylon
- Extractables & leachables (E&L) testing — ICH Q3D, USP <661> compliance
- IQ/OQ/PQ documentation — FDA, EU GMP Annex 1, WHO GMP compliant
Why It Matters
Three Critical Reasons Sterile Filtration Validation Cannot Be Skipped or Simplified
01🦠Microbial Removal & LRV
A 0.2 µm Filter Must Be Validated to Remove Bacteria — Not Just Rated for It
A sterilizing-grade filter is not simply any filter with a 0.2 µm pore size rating. EU GMP Annex 1 and FDA Aseptic Processing Guidance define a sterilizing-grade filter as one that has been validated — by bacterial challenge test using Brevundimonas diminuta (ATCC 19146) at a minimum challenge concentration of 10⁷ CFU/cm² of filter area — to achieve a Log Reduction Value (LRV) of ≥7. This means the filter reduces a bacterial concentration of 10⁷/cm² to an undetectable level in the filtrate. The bacterial challenge test is performed under worst-case conditions for the specific filter membrane, housing and drug product formulation — because some formulations (particularly those containing surfactants, solvents or extreme pH) can compromise membrane performance even when the nominal pore size appears adequate. Microbial removal filtration pharma validation at specification ensures the filter performs in your specific drug product, not just in the manufacturer's standard test fluid.
FDA Warning Letters and EU GMP non-conformances related to sterilizing filtration consistently cite failures in filter validation documentation — particularly the absence of product-specific bacterial challenge data or reliance on generic filter manufacturer data instead of site-specific validation. Regulatory agencies treat this as a critical GMP deficiency.
02🔬Integrity Testing — Pre & Post Use
Post-Use Filter Integrity Test Is the Last Line of Evidence That Sterility Was Maintained
Filter integrity testing pharmaceutical requirements are mandatory at two points for every sterilizing filtration run: before filtration (to confirm the filter is installed correctly and undamaged before the batch is filtered) and after filtration (to confirm the filter remained intact throughout the entire filtration run). The post-use integrity test is the critical one — a pre-use pass followed by a post-use failure means the filter may have been compromised at some point during filtration, and the batch cannot be released on sterility grounds without additional investigation and risk assessment. Bubble point and forward flow diffusion are the two validated methods, both correlating to the bacterial challenge test result; the correlation (the "bubble point-LRV correlation") must be established as part of the filter validation package for the specific filter lot and formulation.
EU GMP Annex 1 §8.95 explicitly states that post-filtration integrity testing of the sterilizing filter should be performed immediately after use. The result must be documented and reviewed before batch certification. A post-use integrity test failure is an Unexpected Event requiring investigation under Chapter 8 deviations.
03⚗️Extractables & Leachables
Filter Extractables Enter the Drug Product — Parenteral Safety Assessment Is Mandatory
Every filter membrane and filter housing component in contact with pharmaceutical drug product is a potential source of chemical contamination through extractables (compounds that migrate under controlled extraction conditions) and leachables (compounds that migrate under actual process conditions and end up in the final drug product). For parenteral drugs administered by injection or infusion, FDA and EMA require a documented extractables and leachables assessment — identifying all compounds migrating from each filter component, quantifying them in the filtered drug product under worst-case conditions, and comparing the levels against ICH Q3D elemental impurities thresholds and compound-specific toxicological thresholds (TTC — Threshold of Toxicological Concern). A filter that passes bacterial challenge and integrity testing but introduces a leachable compound above its safety threshold in the drug product cannot be used for final filtration before drug filling.
ICH Q3D, USP <661> (Plastic Packaging Systems) and the BPOG (BioPhorum Operations Group) Extractables Testing Protocol provide the framework for pharmaceutical filter extractables and leachables studies. Regulatory submission filings for parenteral drug products must include a filter E&L assessment as part of the manufacturing process description.
Product Range
Pharmaceutical Process Filtration Systems — Clarification to Sterilizing Grade
Our pharmaceutical process filtration range covers the complete drug product filtration train — from bulk solution clarification and depth filtration through to validated sterilizing-grade 0.2 µm final filtration and purified water filtration for pharma applications.
⭐ Final Drug Product Filtration 💊
Sterilizing 0.2 µm Membrane Filter
Validated sterilizing-grade liquid filtration for pharmaceutical production — 0.2 µm PES, PVDF or PTFE membrane with bacterial challenge validation (LRV ≥10⁷), bubble point and forward flow integrity test, extractables and leachables testing, and complete IQ/OQ documentation for final filtration before drug filling in aseptic manufacturing.
Technical Specifications
| Rating | 0.2 µm — Sterilizing Grade (0.22 µm nominal) |
| LRV | ≥10⁷ — Brevundimonas diminuta challenge |
| Membrane | PES, PVDF or PTFE — product compatibility |
| Integrity | Bubble point + Forward flow — pre & post use |
| E&L | Extractables tested — ICH Q3D / BPOG protocol |
| Sterilisation | Autoclave / SIP — 134°C/30 min rated |
Applications
Pre-Filtration & Depth 🔩
Clarification & Depth Filter Systems
Upstream pharmaceutical solution filtration system for bulk drug solution preparation — multi-layer depth filtration removing particles, colloids, sub-visible matter and protein aggregates that would prematurely load the sterilizing membrane. Validated throughput and adsorptive capacity data required for scale-up and regulatory filing of the complete filtration train.
Technical Specifications
| Pre-filter | 5–10 µm — bulk particle and precipitate removal |
| Depth Filter | 0.2–0.45 µm — colloid, aggregate, bio-burden reduction |
| Media | Cellulose / DE / PES depth media — product specific |
| Throughput | Validated capacity per specific formulation |
| Housing | 316L SS or single-use — GMP construction |
| Purpose | Protect sterilizing filter — extend service life |
Applications
Water Systems & Utilities 💧
Purified Water & WFI Filtration
Purified water filtration for pharma for Purified Water (PW) and Water for Injection (WFI) distribution systems — 0.2 µm point-of-use filters protecting terminal use points from biofilm migration in distribution loops, with integrity testing, endotoxin-free construction and validated installation meeting USP <1231> and Ph. Eur. 0169 requirements.
Technical Specifications
| Rating | 0.2 µm — biofilm protection at POU |
| Material | PTFE or PES — hydrophilic, low extractables |
| Endotoxin | <0.25 EU/mL — validated rinse protocol |
| Application | PW / WFI / Clean Steam condensate filtration |
| Integrity | Forward flow test — scheduled frequency |
| Standards | USP <1231>, Ph.Eur. 0169, ISPE Water Guide |
Applications
Why Choose Domnick
Benefits of Our Pharmaceutical Process Filtration Systems
A pharmaceutical process filtration system is only as reliable as its validation data, its integrity testing programme and the match between the membrane chemistry and the drug product formulation. We specify and document complete filter trains for pharmaceutical manufacturers throughout Thailand.
01✅
Validated Bacterial Challenge LRV ≥10⁷
Every sterilizing-grade membrane filters for pharmaceutical applications system supplied with bacterial challenge validation data — Brevundimonas diminuta challenge at ≥10⁷ CFU/cm² confirming LRV ≥7 in the specific drug product formulation or worst-case surrogate, meeting EU GMP Annex 1 and FDA Aseptic Processing Guidance requirements.
02🔬
Pre & Post-Use Integrity Testing
Filter integrity testing pharmaceutical programme including bubble point and forward flow procedures, acceptance criteria correlated to bacterial challenge LRV, test equipment calibration and documentation structure — ensuring every batch filtration run produces a complete integrity test record before batch release decision.
03⚗️
Extractables & Leachables Assessment
E&L studies under worst-case conditions — time, temperature, solvent, pH — with identification and quantification of all extractable compounds and patient safety assessment against ICH Q3D and TTC thresholds. Required for parenteral drug product regulatory submissions and critical for qualifying new filter materials in existing processes.
04💧
Staged Train Design — Protect the Sterilizing Filter
Complete staged pharmaceutical process filtration train specification — pre-filter, depth filter and sterilizing filter sized and validated as an integrated system, with throughput data confirming the upstream stages protect the 0.2 µm sterilizing membrane from premature loading across the validated batch size range.
05📋
IQ/OQ/PQ Qualification Documentation
Complete filter system qualification documentation — design specification, installation verification, operational testing (integrity test acceptance criteria, flow rate, pressure limits) and process performance qualification over the validated operating range. Structured for inclusion in FDA and EU GMP regulatory submissions.
06🏭
Single-Use & Reusable System Options
Single-use filter capsules with pre-installed housing for aseptic manufacturing applications where cleaning validation and carryover are unacceptable risks, and reusable multi-use housings with autoclaved cartridges for high-volume applications where validated cleaning and SIP procedures make reuse economically justified and regulatory-compliant.
Applications
Pharmaceutical Process Filtration Applications in GMP Manufacturing
Sterile filtration in pharmaceutical manufacturing applies across every product type and dosage form — each with specific membrane chemistry requirements, integrity test acceptance criteria and regulatory guidance that governs the filtration validation approach.
💉
Parenteral Drug Products
Sterile Injectables & Infusibles
0.2 µm sterilizing final filtration before drug filling for injectables, infusion solutions and lyophilized drug products — dual sterilizing filter configuration required for large-volume parenterals (LVP) per EU GMP Annex 1; PES membrane for aqueous parenterals; PTFE for solvents and high-pH formulations; E&L study mandatory for patient safety filing
EU GMP Annex 1 · FDA Aseptic Guide🧬
Biologics & Vaccines
Bioprocess Final Filtration
Sterilizing filtration for recombinant proteins, monoclonal antibodies, vaccines and cell therapy drug products — protein retention testing to confirm membrane does not adsorb significant drug substance; PVDF membrane preferred for low protein-binding; single-use systems required for containment of biological material; upstream depth filtration for harvest clarification
ICH Q5A · EU GMP Annex 2👁️
Ophthalmic Preparations
Sterile Topical Preparations
0.2 µm sterilizing filtration for eye drops, ophthalmic solutions and contact lens products — low-extractables membrane required as ocular contact area is highly sensitive to chemical irritants; cellulose acetate or PES membrane for aqueous ophthalmic solutions; integrity test mandatory; microbial removal filtration pharma must achieve sterility assurance without heat processing
Ph.Eur. 5.1.1 · EU GMP Annex 1💧
Water for Injection (WFI)
Pharmaceutical Water Systems
Purified water filtration for pharma — 0.2 µm point-of-use filtration on WFI and purified water distribution loops protecting against biofilm detachment and contamination at use points; integrity testing on scheduled frequency; endotoxin-free construction critical; PTFE or hydrophilic PES membrane; compatible with periodic hot-water sanitisation of distribution loop
USP <1231> · ISPE Water Guide🏭
API & Bulk Drug Substance
Active Pharmaceutical Ingredient
Filtration of API solutions, solvent streams and reagents in pharmaceutical synthesis — PTFE membranes for solvent and acid/base streams; PVDF for organic solvent compatibility; depth filtration for product crystallisation mother liquors; liquid filtration for pharmaceutical production during API purification steps must meet ICH Q7 clean utility requirements with documented filter validation
ICH Q7 · EU GMP Part II🌬️
Cleanroom Air & Gas Filtration
Sterile Gases & HVAC
Cleanroom air filtration pharmaceutical — HEPA and ULPA filter systems for pharmaceutical cleanroom air handling; 0.2 µm hydrophobic PTFE membrane filters for compressed gas and nitrogen supply in aseptic manufacturing; HEPA terminal filters in Grade A LAF units and isolators; integrity testing of HEPA installations per ISO 14644-3
EU GMP Annex 1 · ISO 14644 Filtration Science Guide
Pharmaceutical Filtration Train Design, Membrane Chemistry Selection & Validation Requirements
Designing a compliant pharmaceutical process filtration system requires three parallel decisions: what sequential filter stages protect the sterilizing membrane, what membrane chemistry is compatible with the drug product formulation, and what validation testing the regulatory agencies require for each filter type and application. This guide covers all three systematically.
Pharmaceutical Drug Product Filtration Train — Sequential Stages & What Each Removes
1 Stage 01 · Clarification
Pre-Filtration
5–10 µm nominal
Removes
- Visible particles & fibres
- Excipient precipitates
- Rust and equipment particulate
- Protects depth filter media
2 Stage 02 · Sub-Micron
Depth Filtration
0.2–0.45 µm depth media
Removes
- Sub-micron particles & colloids
- Protein aggregates (biologics)
- High bio-burden reduction
- Protects sterilizing membrane
3 Stage 03 · Sterilizing
0.2 µm Sterile Filter
LRV ≥10⁷ · Integrity Tested
Removes
- All bacteria & micro-organisms
- Spores and mycoplasma
- Sub-visible bio-burden
- Pre & post integrity test
4 Stage 04 · Fill
Sterile Drug Filling
Grade A · Aseptic Process
Output
- Sterile drug product — batch released
- Batch sterility test (if required)
- Post-filtration integrity test
- Complete filtration batch record
Membrane Chemistry Selection for Pharmaceutical Applications
The membrane polymer chemistry determines compatibility with the drug product formulation, extractables profile, protein binding behaviour, and maximum operating temperature for SIP/autoclave sterilisation. Selecting the wrong membrane for a drug product formulation can cause drug adsorption, membrane degradation or unacceptable extractables levels in the filtered product.
PES Primary choice — aqueous
Polyethersulfone
Best for: Aqueous parenteral formulations, buffer solutions, biological drugs, vaccine manufacturing and most aqueous drug product streams. Low protein binding and low extractables make PES the default first choice for biologics and parenteral filtration.
Not suitable for strong solvents, concentrated acids/bases or hydrophobic formulations containing high organic solvent content.
Low E&L Low Protein Binding SIP/Autoclave Organic Solvents ✗
Parenterals Biologics Vaccines WFI/PW
PVDF Bioprocess & low-binding
Polyvinylidene Fluoride
Best for: Biopharmaceutical processes with high-value protein drugs where minimal drug adsorption is critical. Excellent chemical resistance to a wide range of organic solvents and aggressive formulations. Standard choice for monoclonal antibodies and recombinant proteins.
Higher cost than PES. Requires hydrophilic surface modification for aqueous pharmaceutical applications — confirm hydrophilic grade is specified.
Very Low Protein Binding Chemical Resistance Solvent Compatible SIP Compatible
mAb Recombinant Protein Solvents Organic API
PTFE Gases, solvents & aggressive chemistry
Polytetrafluoroethylene
Best for: Pharmaceutical-grade compressed gases and nitrogen, organic solvents and solvent-based drug formulations, aggressive acids/bases and API synthesis filtration. Hydrophobic by nature — the standard for gas and solvent filtration; hydrophilic PTFE available for aqueous applications.
For gas applications: always use hydrophobic PTFE. For aqueous: specify hydrophilic grade — integrity test with water, not isopropanol.
Gas Filtration Solvent Resistant Acid/Base Stable Aqueous — specify grade
N₂/Gas Filtration Solvents API Synthesis Acid/Base
NYL Aqueous & mild solvents
Nylon (Polyamide 6,6)
Best for: Aqueous drug products at neutral-to-mildly-acidic pH, mild organic solvents and alcohol-containing pharmaceutical preparations. Lower cost than PES or PVDF with acceptable performance for many standard pharmaceutical formulations that are not highly potent biologics.
Not recommended for strong acids (pH <3), oxidising agents or high-concentration organic solvents. Higher protein binding than PES or PVDF — not preferred for biologics.
Aqueous Compatible Mild Solvents Strong Acid ✗ High Protein Binding
Aqueous Drug Soln. Alcohols QC Laboratory Buffer Filtration
Pharmaceutical Filter Validation Requirements by Application & Regulatory Agency
Different pharmaceutical filtration applications carry different validation requirements under EU GMP Annex 1, FDA Aseptic Processing Guidance, WHO TRS and USP. The table below maps each key validation element to its requirement status — mandatory, conditionally required or recommended — by application type. Note that "conditionally required" means required when specific risk factors are present (e.g. E&L testing is conditionally required for non-parenteral routes but mandatory for parenterals).
| Validation Element | Parenteral Drug Product | Biologics / Vaccine | Ophthalmic | API Solution (ICH Q7) | WFI / PW Filtration |
|---|---|---|---|---|---|
| Bacterial Challenge (LRV ≥7) | Mandatory — product-specific | Mandatory — protein-compatible | Mandatory | Conditional — sterile API only | Recommended |
| Pre-Use Integrity Test | Mandatory — every batch | Mandatory — every batch | Mandatory | Mandatory | Mandatory — scheduled |
| Post-Use Integrity Test | Mandatory — every batch | Mandatory — every batch | Mandatory | Mandatory — sterile API | Recommended |
| Extractables & Leachables | Mandatory — ICH Q3D, BPOG | Mandatory — BLA/MAA filing | Conditional — product-specific | Conditional — ICH Q3D limits | Recommended |
| Protein Retention Test | Recommended — high-value drugs | Mandatory — protein drugs | Recommended | Recommended — protein API | N/A |
| Filter Throughput / Capacity | Mandatory — scale-up data | Mandatory — scale-up data | Mandatory | Conditional | Recommended |
| Sterilisation Compatibility | Mandatory — SIP/autoclave cycles | Mandatory — SIP/autoclave | Mandatory | Conditional — SIP systems | Mandatory — hot water compat. |
Standards & Compliance
EU GMP Annex 1 (2022) FDA Aseptic Processing Guidance USP <1229.3> USP <1231> ICH Q7 ICH Q3D ISO 14644 ISPE Sterile Filtration Guide
Design Your Validated Pharmaceutical Process Filtration System
Our pharmaceutical filtration specialists design and validate complete process filtration systems for pharmaceutical manufacturers throughout Thailand. From membrane selection and bacterial challenge validation planning to integrity testing programs, extractables and leachables (E&L) study scope definition, and IQ/OQ/PQ qualification documentation, we deliver reliable filtration solutions for regulated pharmaceutical manufacturing environments.
Get expert guidance when you need it. Our support team is here to provide you with the right solutions.
